-
Jul 1, 2024 | 
eprints.gla.ac.uk | Zi Michael |Mc Causland |Carolyn S.P |Bomfim Wirtz
Ostrominski, J. W. et al. (2024) Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction a trial-level analysis. Journal of the American College of Cardiology, 84(2), pp. 223-228. (doi: 10.1016/j.jacc.2024.05.005) (PMID:38744407) Text329241.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. 284kBAbstractNo abstract available.
-
Mar 5, 2024 | 
eprints.gla.ac.uk | Zi Michael |John J.V |Philippe Gabriel |van der Meer
Mann, D. L. et al. (2024) Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI. Journal of the American College of Cardiology, 83(9), pp. 904-914. (doi: 10.1016/j.jacc.2024.01.002) (PMID:38418004) Full text not currently available from Enlighten.
-
Mar 4, 2024 | 
eprints.gla.ac.uk | Zi Michael |G. G. Michael |John J.V |GALACTIC-HF Investigators
Adamo, M. et al. (2024) Tricuspid regurgitation and clinical outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 12(3), pp. 552-563. (doi: 10.1016/j.jchf.2023.11.018) (PMID:38300212) Full text not currently available from Enlighten. AbstractBackgroundTricuspid regurgitation (TR) is common and is associated with poor outcomes in patients with heart failure (HF).
-
Feb 6, 2024 | 
eprints.gla.ac.uk | Carolyn S.P |Vinh Nguyen |Zi Michael |De Boer
Wang, X. et al. (2024) Effects of dapagliflozin in patients in Asia: a post hoc subgroup analysis from the DELIVER trial. JACC: Asia, 4(2), pp. 108-118. (doi: 10.1016/j.jacasi.2023.10.005) (PMID:38371292) (PMCID:PMC10866733) Text319440.pdf - Published Version Available under License Creative Commons Attribution.
-
Dec 12, 2023 | 
eprints.gla.ac.uk | Zi Michael |Carolyn S.P |De Boer |Maria Langkilde
Ostrominski, J. W. et al. (2023) Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: The DELIVER trial. Circulation, 148(24), pp. 1945-1957. (doi: 10.1161/circulationaha.123.065254) (PMID:37830208) Full text not currently available from Enlighten.
-
Nov 6, 2023 | 
eprints.gla.ac.uk | Zi Michael |Julio Núñez |van der Meer |Freny Vaghaiwalla
Schou, M. et al. (2023) Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3079) (PMID:37933184) (Early Online Publication)Full text not currently available from Enlighten.
-
Nov 6, 2023 | 
eprints.gla.ac.uk | Zi Michael |Carolyn S.P |De Boer |Anna Maria
Ostrominski, J. W. et al. (2023) Cardio-renal-metabolic overlap, outcomes, and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC: Heart Failure, 11(11), pp. 1491-1503. (doi: 10.1016/j.jchf.2023.05.015) (PMID:37226448) Text312850.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives.
-
Oct 18, 2023 | 
eprints.gla.ac.uk | van der Meer |Zi Michael |Philippe Gabriel |De Pasqulae
Petrie, M. C. et al. (2023) Pulmonary congestion and left ventricular dysfunction after myocardial infarction: insights from the PARADISE-MI trial. Circulation, (Accepted for Publication)Text308460.pdf - Accepted Version Restricted to Repository staff only610kBItem Type:ArticlesAdditional Information:PARADISE-MI was funded by Novartis. Drs Petrie and McMurray are supported by the British Heart Foundation (BHF) Centre of Research Excellence Award (RE/13/5/30177 and RE/18/6/34217+).
-
Sep 28, 2023 | 
eprints.gla.ac.uk | Zi Michael |Carolyn S P |De Boer |Anna Maria
Bhatt, A. S. et al. (2023) Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3043) (PMID:37771274) (Early Online Publication)Text307595.pdf - Accepted Version Restricted to Repository staff only until 28 September 2024. 486kBAbstractIntroduction:COVID-19 may affect clinical risk in patients with heart failure.
-
May 22, 2023 | 
eprints.gla.ac.uk | Mc Causland |Zi Michael |De Boer |Carolyn S P
Chatur, S. et al. (2023) Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: insights from the DELIVER trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.2915) (PMID:37212168) (Early Online Publication)Text299608.pdf - Accepted Version Restricted to Repository staff only until 22 May 2024.
